INTRODUCTION
Pre-eclampsia is a syndrome that is usually defined as the onset of hypertension and proteinuria after 20 weeks of gestation in previously normotensive non-proteinuric pregnant women. 1 If left untreated, pre-eclampsia can progress to a convulsive state known as eclampsia. 2 Pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality. 3, 4 In the Western world, it affects between 2 and 7% of all pregnancies, but the incidence in other geographic areas with different ethnic or social characteristics can be up to three times greater. 5, 6 A worldwide incidence of 8,370,000 cases per year has been estimated. 5, 6 In developing countries, such as Colombia, 42% of maternal deaths are attributed to this disorder, which is also the major reason for premature delivery. 7 The incidence of eclampsia is also high in develop ing countries (1.6 and 12 per 1,000 live births, respectively, in Colombia and India). 8 
RISK FACTORS
Pre-eclampsia is primarily regarded as a disease of first pregnancy, although the protective effect of multiparity is said to be lost with change of partner. 9 This supports the hypothesis that risk is reduced with repeated exposures to specific antigens from the same partner; however, recent evidence from the Medical Birth Registry of Norway indicates that the protective effect of previous pregnancy with the same partner is confounded by the time interval between births. 10 These data, obtained from >1.8 million births over 31 years, showed that when the birth interval was >10 years, a multiparous woman had the same risk of developing pre-eclampsia as a primiparous woman. It has, however, been suggested that this 'birth-interval hypothesis' is not well founded. 11 A systematic review of >1,000 controlled studies published from 1966 to 2002 found that Pre-eclampsia, a syndrome of pregnant women, is one of the leading causes of maternal and fetal morbidity and mortality. Despite active research, the etiology of this disorder remains an enigma. Recent work has, however, provided promising explanations for the causation of the disorder and some of its phenotypes. Evidence indicates that the symptoms of hypertension and proteinuria, upon which the diagnosis of pre-eclampsia is based, have several underlying causes. Nevertheless, the treatment of pre-eclampsia has not changed significantly in over 50 years. This review describes the most recent insights into the pathophysiology of preeclampsia from both basic and clinical research, and attempts to provide a unifying hypothesis to reconcile the abnormalities at the feto-placental level and the clinical features of the maternal syndrome. The novel findings outlined in this review provide a rationale for potential future prophylactic and therapeutic interventions for pre-eclampsia. a previous history of pre-eclampsia, multiple pregnancy, nulliparity, pre-existing diabetes, high BMI before pregnancy, maternal age ≥40 years, renal disease, hypertension, ≥10 years since previous pregnancy and presence of antiphospholipid antibodies all increased a woman's risk of developing pre-eclampsia. 12 Increases in risk of more than ninefold, sevenfold and threefold, respectively, were documented for antiphospholipid antibodies, previous history of pre-eclampsia and diabetes. Based on this evidence, guidelines for risk assessment of pre-eclampsia have recently been issued. 13 Other risk factors for pre-eclampsia are insulin resistance in concert with obesity 14, 15 and thrombo philia. 16 In developing countries, protein-calorie undernutrition has been identified as an important risk factor; 17 however, a negative correlation between calcium intake and incidence of pre-eclampsia has recently been detected in Guatemala, Colombia and India. 7 This finding is supported by the observation that calcium supplementation is beneficial to women at high risk of gestational hypertension, and in communities with low dietary calcium intake. [18] [19] [20] 
Genetic factors
The precise role of genetic factors in the development of pre-eclampsia is unclear, and no specific contributory gene has been identified. The inheritance pattern of the disease has been described as Mendelian (autosomal recessive and autosomal dominant with incomplete penetrance), polygenic/multifactorial and mitochondrial. Small studies [21] [22] [23] [24] have indicated an association between pre-eclampsia and polymorphisms of genes that control blood pressure, co agulation or oxygen-free-radical meta bolism-such as renin, angio tensinogen, endothelial nitric oxide synthase (eNOS), FACTOR V LEIDEN, METHYLTETRAHYDROFOLATE or lipo protein lipase-but this has not been confirmed. 25 Linkage analysis has identified three potential loci linked to susceptibility to pre-eclampsia: 2p13, 2p25 and 9p13. 26, 27 Notably, these loci account for only a small percentage of cases (other studies failed to confirm the associations). 28,29 A fourth locus for pre-eclampsia was subsequently identified on 10q22. Maximal allele sharing between pre-eclamptic sisters at this locus was observed for maternal-derived but not paternal-derived alleles, 30 indicating matrilineal inheritance.
The STOX1 gene in the 10q22 locus contains five different missense mutations. STOX1 is identical in affected sisters, co-segregates with the pre-eclamptic phenotype and is inherited matrilineally. 31 A role has been proposed for the gene product (a DNA-binding protein) in controlling polyploidization of extravillous trophoblasts, although its precise biological function has not been clarified. 31 In a large study by the British Genetics of Preeclampsia Consortium, 657 women affected by pre-eclampsia and their families were genotyped at sites of 28 single-nucleotide polymorphisms in several genes, including those involved in angiotensin activity (angiotensinogen and angiotensin II type 1 receptor [AT1]) and oxidative stress (methylene tetrahydrofolate reductase). 32 None of the genetic variants tested were found to confer a high risk of disease development, indicating that alterations of angiotensin activity and oxidative stress are not prime causes of pre-eclampsia.
DIAGNOSIS AND CLINICAL FEATURES
The cardinal features of pre-eclampsia are hypertension and proteinuria. In the past, hypertension indicative of pre-eclampsia was defined as an elevation of >30 mmHg systolic pressure or >15 mmHg diastolic pressure above the patient's baseline blood pressure. This definition proved to be a poor indicator of outcome 33 and, in 2000, the criteria were refined by the National High Blood Pressure Education Program (NHBPEP) Working Group. 1 Since then, there has been considerable agreement between international working groups. 34 The criteria define hypertension as a systolic blood pressure ≥140 mmHg or a diastolic level (Korotkoff 5) ≥90 mmHg on two or more occasions at least 4-6 h (but not more than 7 days) apart after 20 weeks of gestation in a woman with previously normal blood pressure. Nevertheless, the NHBPEP working group report 1 also stated the collective opinion that 30 mmHg systolic and 15 mmHg diastolic increases, even at values <140/90 mmHg, should prompt patient monitoring for pre-eclampsia.
For most healthy, nulliparous women, the factor that differentiates pre-eclampsia from other gestational hypertensive disorders is con comitant proteinuria, defined as ≥0.3 g protein in a 24 h urine sample. 1 When daily urine collection is not feasible, two random urine samples taken at least 4-6 h apart are usually acceptable. 1 correlation between random protein concentration or urinary dipstick measurements and 24 h protein excretion in women with gestational hyper tension, [35] [36] [37] it is best to base diagnosis of proteinuria on quantitative measurement of 24 h urine samples.
The diagnostic criteria outlined above do not apply to women who have hypertension or proteinuria before 20 weeks of gestation. 38, 39 Thus, pre-eclampsia can also occur in women with pre-existing chronic hypertension, a condition that is often worsened by gestation (Box 1). 1 More stringent diagnostic criteria are necessary, including a sudden exacerbation of hyper tension, new onset or sudden exacerbation of proteinuria, thrombocytopenia and elevated levels of liver enzymes. 1 Pre-eclampsia is regarded as severe if one or more of the criteria in Box 2 are fulfilled. 40 As well as hypertension and proteinuria, preeclampsia can be associated with edema, visual disturbances, headache, and epigastric or right upper-quadrant pain with nausea and vomiting (Box 3). Hemolysis, elevated liver enzymes and thrombocytopenia are characteristic laboratory features of a severe variant of pre-eclampsia, the HELLP SYNDROME, which occurs in 5-8% of pre-eclamptic women. 40 This multisystem, pregnancy-specific condition illustrates that pre-eclampsia can affect every maternal organ, predominantly the vascular, renal, hepatic, cerebral and coagulation systems (Box 3). Kidney function, with its reliance on adequate glomerular blood flow and selective permeability of glomerular capillaries, is particularly susceptible to the endothelial changes in pre-eclampsia that ■ Supine blood pressure ≥160 mmHg systolic or ≥110 mmHg diastolic on two occasions at least 6 h apart ■ Proteinuria ≥5 g in a 24 h urine specimen or ≥3+ on two random urine samples collected at least 4 h apart ■ Oliguria of <500 ml in 24 h ■ Cerebral disturbances (altered mental status, headache) or visual disturbances (blurry vision, blindness) ■ Pulmonary edema or cyanosis ■ Epigastric or right upper-quadrant pain ■ Impaired liver function ■ Thrombocytopenia (platelet count <100,000/μl) ■ Fetal growth restriction Note: Pre-eclampsia is regarded as 'severe' in the presence of multiorgan involvement, thrombocytopenia, abnormal liver enzymes associated with persistent epigastric pain or persistent and severe central nervous system symptoms. 136 
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HELLP SYNDROME Hemolysis, elevated liver enzymes and thrombocytopenia Box 3 Clinical features of the maternal syndrome of pre-eclampsia.
■
Hypertension: systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg 1 ■ Proteinuria: urinary protein excretion >300 mg/day; preservation of podocyte foot processes in the presence of substantial proteinuria 137 
Decreased plasma volume: contracted by 30-40% compared with normal pregnancy 138 
Edema: interstitial fluid retention; multifactorial 138 (observed in >50% of normal gravidas)
Decreased renal blood flow: renal perfusion less than in normal pregnant women 101 
Increased plasma uric acid: secondary to reduced uric acid renal clearance 139 
Increased aminotransferases and lactate dehydrogenase: hepatocellular necrosis with leakage of liver enzymes into maternal blood 140 
Cerebral edema: due to hypertension and vascular autoregulatory dysfunction 141 
Thrombocytopenia: platelet count <150,000 cells per cubic millimeter 142 
Abnormalities of the coagulation system: changes in the coagulation cascade and fibrinolytic system 143 manifest functionally as vascular constriction, decline in renal blood flow and glomerular filtration rate, and clinically significant proteinuria. 41 Oliguria or anuria can occur in patients with severe pre-eclampsia as a result of low cardiac output and high systemic vascular resistance, 42 but acute renal failure is unusual. 41 Pre-eclampsia can rapidly progress to a convulsive phase termed eclampsia, especially if untreated. 2 The onset of eclampsia can be preceded by severe persistent headache and visual changes. The seizures and mental status changes of eclampsia are often, although not always, related to hypertensive encephalopathy. Maternal death is more likely in the presence of severe hypertension and eclampsia. Notably, the risk of cardiovascular complications later in life is increased in women who develop pre-eclampsia. This could be a function of the numerous risk factors and pathophysiological abnormalities that are shared by pre-eclampsia and coronary artery disease. 43 Impaired uteroplacental blood flow or placental infarction in pre-eclampsia can affect the fetal-placental unit, causing intrauterine growth restriction, intrauterine fetal demise, oligohydramnios, or placental abruption. Generally, maternal and perinatal outcomes are better in mild pre-eclampsia that develops after 36 weeks of gestation than in cases that are symptomatic before 33 weeks of gestation. 1, 6, 44, 45 Maternal and perinatal morbidity and mortality are increased in women with pre-existing medical dis orders 36, 39, 46 and in developing countries. 1, 47 Screening of pregnant women for preeclampsia based on functional or bio chemical tests, such as evaluation of placental per fusion and vascular resistance by Doppler scan, or measurement of markers of endothelial and oxidative stress, has been proposed. 48 Unfortunately, the search for clinically useful screening tests has been dis appointing, as shown in a recent analysis of 87 studies in 211,369 women. 48 Other researchers assert that bio chemical and/or hemodynamic markers are reliable predictive tools for pre-eclampsia. 49 Uterine artery Doppler waveform analysis is used extensively in academic centers to identify women at risk of pre-eclampsia. Studies of Doppler waveform analysis as a screening test for adverse pregnancy outcomes have, however, generated conflicting results, probably due to differences in gestational age at time of examination and the lack of standardized analysis. 50 
PATHOGENETIC MECHANISMS: RECENT INSIGHTS
Efforts to unravel the pathogenesis of preeclampsia have been hampered by the lack of clear diagnostic criteria for the disease and its subtypes. Consequently, several studies have included a variety of other conditions that do not necessarily reflect an adverse pregnancy outcome. More importantly, the definition of pre-eclampsia proposed in 2000 was designed for clinical use, to maximize sensitivity at the detriment of specificity (the risk of not detecting pre-eclampsia far outweighs the risks of over diagnosis and overtreatment). In addition, most pathogenetic studies use specimens from patients with established pre-eclampsia rather than those obtained before clinical onset. This makes it difficult to define a clear relationship between specific mediators, mechanisms and clinical manifestations. Animal models have failed to provide definitive insights into the pathogenesis of pre-eclampsia because of their limited applicability to the human form of the disease. Despite these limitations, several theoretical mechanisms have been proposed that reconcile feto-placental abnormalities and clinical features of the maternal syndrome.
The feto-placental level
For pregnancy to proceed normally, the early blastocyst must adhere to and invade the uterine endometrium so that maternal blood can effectively bathe the PLACENTAL COTYLEDONS. 51 During this process, extra villous cytotrophoblast cells proliferate from the tips of anchoring chorionic villi to form a 'shell' lining the uterine cavity. Two populations of invasive extravillous trophoblasts have been identified. Interstitial trophoblasts invade the decidual stroma and reach the myometrium. At the end of their invasion path, these cells fuse to form multinuclear giant cells. 52 Interstitial trophoblasts might release vasodilators (e.g. NO and carbon monoxide) that act on the spiral arteries before destruction by endovascular trophoblasts. 52 Endovascular cytotrophoblasts invade the lumen of the uterine spiral arterioles, anchor to the vessel wall, and promote arteriole dilation. Thus, by the second trimester, the endometrial and super ficial myometrial segments of spiral arteries are lined by cells of cyto trophoblastic origin, which changes them from small resistance vessels to flaccid, high-caliber capacitance vessels. This remodeling, which transforms the endometrium GLOSSARY PLACENTAL COTYLEDONS The 10-15 portions into which the placenta is divided by intervillous septi CYTOTROPHOBLAST Specialized (fetal) epithelial stem cells of the placenta that differentiate and invade the uterine wall, where they also breach maternal blood vessels
SPIRAL ARTERIES
Maternal uterine vessels that, during placenta development, are remodeled into lowresistance vessels that cannot constrict
into a yet more developed tissue (the deciduas) is instrumental in ensuring adequate perfusion of the feto-placental unit.
Endovascular invasion does not proceed beyond the superficial portions of the uterine spiral arterioles, which retain their endo thelial lining and muscular wall, and functionally remain relatively narrow-bore, high-resistance vessels. 53 The net result is that blood flow into the intervillous space is dramatically reduced. Thus, it was thought that the principal defect in pre-eclampsia relates to endovascular trophoblast invasion and that interstitial trophoblast invasion is normal. 54 Recent quantitative studies, however, of interstitial trophoblast invasion in uterine tissues taken from hysterec tomies following cesarean section in women with pre-eclampsia, have revealed that both the invasive depth and numerical density of interstitial trophoblasts are significantly reduced. 55 Failure of vascular invasion could, therefore, be preceded by impaired interstitial trophoblast invasion. Some patients with preeclampsia at term do not show severe growth restriction. Their placental histomorphometry is similar to that of normotensive gestational age-matched controls. Usually, however, preterm placentas of women with pre-eclampsia are characterized by vascular and occlusive lesions that have been classified according to particular patho physiological processes. 56, 57 Factors involved in abnormal placentation Basic research and clinical data indicate that the maladaptation and inadequate invasion of uteroplacental arteries characteristic of pre-eclampsia result from intrinsic factors (abnormal biology of extravillous trophoblasts) acting in concert with extrinsic maternal uterine factors. These extrinsic factors, operating around the uteroplacental arteries, comprise impaired decidual remodeling, impaired function of uterine natural killer (NK) cells and maternal endothelial failure to express adhesion molecules. These factors might interact in a cascade-like fashion.
NK cells are the predominant population of decidual lymphoid cells. During early pregnancy they accumulate as a dense infiltrate around the invading cytotrophoblast cells. They cooperate with extravillous trophoblasts to remodel spiral arteries by producing cytokines that are involved in angiogenesis and vascular stability, such as vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and ANGIOPOIETIN . 58 Although the villous trophoblast cells exposed to maternal blood lack MHC class I and class II molecules, the invading cytotrophoblast expresses an unusual combination of the former: HLA-C, HLA-E and HLA-G. These molecules interact with receptors on the surface of NK cells, such as killercell immunoglobulin-like receptors (KIRs) and CD94. The ligand-receptor pairs might control the interaction of extravillous trophoblast cells and decidual NK cells. The human KIR locus consists of 7-15 closely packed genes on chromosome 19q, which encode both inhibitory and activating KIRs. These genes form numerous haplotypes that differ in both gene content and allele combinations.
Both HLA-C and KIR genes are polymorphic in humans, so every pregnancy has different combinations of paternally derived fetal HLA-C on trophoblasts and maternal KIRs on NK cells. 59 Pre-eclampsia is more prevalent in women who are homozygous for group A KIR haplotypes (which contain mainly genes encoding inhibitory KIRs) than in women who are homozygous for group B haplotypes (which contain genes for activating KIRs) or those who are heterozygous. 60 Moreover, it is the combination of fetal HLA-C2 genotype-the product of which binds more tightly to its cognate KIR than C1 product-and maternal AA KIR genotype that most frequently leads to pre-eclampsia. 60 This combination is predicted to deliver the strongest inhibitory signals from extravillous trophoblasts to NK cells. It has therefore been proposed that inhibition of uterine NK cells has a role in defective trophoblast remodeling of maternal blood vessels; however, only a minority of pregnancies with C2 fetuses and AA mothers result in preeclampsia. This finding, along with the observation that not all pre-eclamptic pregnancies have the C2-AA genotype combination, indicates that additional factors are involved.
In normal pregnancy, as they invade the uterine wall, cytotrophoblasts lose the ability to divide and upregulate expression of matrix metallo proteinases, thereby promoting transformation of epithelial tissue to endo thelium. 61 Zhou et al. 61 have shown that invasive cytotrophoblasts downregulate epithelial-like receptors such as endo thelial (E)-cadherin and α 6 β 4 , which are replaced by endothelial ad hesion molecules, such as platelet-endo thelial celladhesion molecule (PECAM), vascular endothelial (VE)-cadherin, vascular cell-adhesion molecule 1 (VCAM1), and α 4 and α v β 3 integrins. 61
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ANGIOPOIETIN 2
Endothelium-specific ligand that modulates angiogenesis and vascular permeability
CD94
Inhibitory and activating C-type lectin-like natural killer receptors that primarily recognize HLA-E molecules and HLA-G/C leadersequence peptide
In pre-eclampsia, this transformation is impaired, and cytotrophoblasts do not invade and differentiate. Immunohistochemical staining of preeclamptic placental bed biopsies shows very low levels of VE-cadherin, VCAM1 and α v β 3 integrin, 53 indicating that the cells fail to acquire an endothelial phenotype.
One hypothesis attributes this impaired transformation to insufficient local concentrations of angiogenic factors, including VEGF and PlGF, which are expressed at high levels during normal placentation. 62 VEGF induces endothelial cell expression of α v β 3 integrin, a molecule associated with angiogenesis and cytotrophoblast invasion. 61 Furthermore, cyto trophoblasts have VEGF receptors, including the Fms-like tyrosine kinase 1 (Flt1) receptor (also known as VEGF receptor-1). 63 As high levels of Flt1 are found in invasive cyto trophoblasts as early as 6 weeks postfertilization, 63 interaction of the receptor with VEGF and PlGF has been considered crucial for invasion and PSEUDO-VASCULOGENESIS. This possibility is supported by the fewer cellto-cell inter connections and decreased expression of integrin α 1 . These accurate indices of defective cells' invasive capacity are observed in human cytotrophoblasts in vitro when an Flt1-Fc fusion protein that blocks binding of VEGF and PlGF to the Flt1 receptor is added to the culture medium. 63 Pre-eclamptic placentas have decreased levels of VEGF messenger RNA, 64 supporting the hypothesis that VEGF is involved in abnormal, shallow placentation.
Cytotrophoblast immunostaining for VEGFA and Flt1 63 is reduced in pre-eclampsia compared with normal pregnancy. Most Flt1 produced in the human placenta during later stages of gestation is a soluble form (sFlt1) generated by alternative splicing. sFlt1 lacks the trans membrane and cytoplasmic domains of Flt1, and is released in large amounts into the blood, 65 where it reduces levels of free VEGF via soluble antagonism of both factors. 65 Cytotrophoblasts isolated from pre-eclamptic placentas released more sFlt1 than those from normal placentas, 63 and up regulation of sFlt1 messenger RNA has been detected in preeclamptic placentas. 66 So, by preventing binding of VEGF to Flt1 receptors on cyto trophoblast cells, excessive production of sFlt1 in placental trophoblasts could be responsible for the defective cytotrophoblast differentiation and abnormal placentation of pre-eclampsia. However, chimeric placentas from tetraploid aggregates-comprising trophoblasts homozygous for a null allele of Flt1 and the normal Flt1 +/+ maternal and fetal components-showed no defective formation of placental circulation or endovascular trophoblast invasion of maternal spiral arteries. 67 The chimeric placentas supported normal fetal growth 67 indicating that, in mice, expression of Flt1 in trophoblasts is not essential to normal placentation. Whether this observation is applicable to humans is not known; mouse placenta does not undergo the same degree of placental vascular remodeling and invasion as human placenta.
As insightful as these findings are, they do not answer the question of whether altered VEGF-Flt1 signaling has a role in the impaired placental vasculogenesis and maternal spiral uterine-artery remodeling of pre-eclampsia. Interestingly, the VEGF-Flt1 interaction induces release of NO, 68 a potent vasodilator synthesized from the amino acid l-arginine (l-Arg) by the NOS family of isoenzymes 69 ( Figure 1 ). Human placenta does not form inducible or neuronal NOS, 70 but eNOS is found in the endothelium of the umbilical cord, in the chorionic plate, and in villous cytotrophoblasts. 70 Several reports have described intense eNOS expression in extravillous trophoblast cells. [71] [72] [73] [74] This finding could not, however, be confirmed by others. 75 In trophoblast cells, NO upregulates expression and activity of the matrix-degrading proteases MMP2 and MMP9, which are required for in vasion during embryo implantation. 76 MMP2 also has a pivotal role in the relaxin-gelatinase pathways that are upregulated during pregnancy and contributes to reduced myogenic reactivity of small arteries through activation of the endothelial endothelin B receptor-NO pathways. 77 NO release has been shown to mediate angiopoietin-induced growth and migration of extravillous trophoblast cell lines in vitro. 78 NO is coupled through Flt1 signaling to cyto trophoblast invasion and motility induced by VEGF. 79 It also mediates VEGF-induced up regulation of VE-cadherin in endo vascular trophoblasts, 80 all processes necessary for placental development. By virtue of these unique vaso dilatory and angiogenic/vasculogenic properties, locally generated NO seems to be instrumental in promoting cytotrophoblast endovascular invasion during normal placenta tion. 61 Thus, it is possible that the placental changes of pre-eclampsia reflect a reduced capacity of cyto trophoblast cells to form NO.
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PSEUDO-VASCULOGENESIS
The diminished NO activity of pre-eclamptic placenta cannot be the consequence of a defect in NO-forming enzyme, because placentas of pre-eclamptic women express normal levels of eNOS and form normal amounts of NO. 70, 81 Instead, it results from reduced activity or halflife of NO. This translates into lower concentrations of cyclic GMP (the NO intracellular second messenger) in the placental circulation compared with normal pregnancy. 70 A plausible explanation for reduced NO activity is that, in pre-eclamptic placenta, NO is rapidly degraded to peroxy nitrite (ONOO -), a potent cytotoxic anion devoid of angiogenic properties. 82 This explanation is supported by intense immunostaining for nitrotyrosine (a marker of ONOOformation in vivo) observed in fetal blood vessels of floating villi, syncytio trophoblasts and in vasive cyto trophoblasts. 83 Data indicate that NO interacts with reactive oxygen species (ROS), including superoxide anion (O 2 -), which are abundant in pre-eclamptic placenta compared with normal placenta. 83 A biochemical explanation for excessive ROS production in pre-eclampsia has been proposed. In addition to synthesizing NO, NOS facilitates production of superoxide anion (O 2 -). 84 The relative amounts of NO and O 2 -formed are tightly regulated by intracellular levels of l-Arg. 85, 86 In the presence of sufficient l-Arg, NOS in cultured mouse macrophages and human kidney cells 85,87 generated only NO. Depletion of l-Arg led to production of both NO and O 2 -, and subsequent formation of ONOO -. It is reasonable to propose that a similar biochemical aberration in NOS function might occur in pre-eclamptic placenta, as l-Arg levels are lower than normal in preeclamptic villous tissue 88 as a consequence of l-Arg consumption by arginase II. This enzyme, which degrades l-Arg to ornithine and urea, 89 is markedly expressed in pre-eclamptic, but not normal, trophoblast cells. 88 The mechanism of arginase II upregulation in pre-eclampsia is unknown, but testosterone-which stimulates arginase II activity in female mice and rats 90 and is present at higher levels in pre-eclampsia than in normal pregnancy 90, 91 -is a potential mediator (Figure 1) .
The role of subnormal l-Arg/NO activity in sustaining deficient spiral artery invasion in pre-eclampsia is underscored by the recent finding that long-term l-Arg supplementation in women at risk of placentation disorders reduces uterine artery resistance, allows delivery at term and improves perinatal outcome. 92 Conversely, chronic administration of the l-Arg antagonist nitro-l-Arg-methyl-ester to pregnant rats induces a pre-eclampsia-like syndrome characterized by sustained hypertension, proteinuria and intrauterine growth retardation. 93 It also increases levels of blood and tissue markers of oxidative stress, further supporting the link between l-Arg deficiency and oxidative stress of pre-eclampsia. In this model, treatment with the antioxidants glutathione and quercetine normalized plasma levels of peroxidation products, and reduced proteinuria and the pup mortality rate. 94 Defective NO-mediated vasodilatation conceivably translates into the relative vasoconstriction of feto-placental vessels and inadequate perfusion that characterize severe pre-eclampsia. The direct consequence of abnormal cytotrophoblast differentiation is placental hypoperfusion and ischemia, which trigger production of factors that might drive both the fetal and maternal syndromes. Hypoxiainducible factor 1α (HIF1α), a subunit of HIF1, is overexpressed in trophoblast cells of preeclamptic placenta. 52, 95, 96 HIF1 mediates cellular adaptations to low-oxygen conditions by activating transcription of several genes. In human villous explants under low-oxygen tension, HIF1 upregulates expression of transforming growth factor-β3 (TGF-β3), 97 a potent inhibitor of early trophoblast differentiation. 98 TGF-β3 is overexpressed in pre-eclamptic placenta. 95 Its inhibition by antisense oligonucleotides in preeclamptic villous explant cultures restores the invasive capabilities of trophoblast cells, 98 indicating that HIF1-mediated TGF-β3 expression could have a role in trophoblast dysfunction in pre-eclampsia.
In addition, placenta hypoperfusion and, particularly, intermittent perfusion, create a condition of hypoxia-reoxygenation that favors oxidative damage. 99 Hypoxia increases activity of xanthine oxidase (XO), 100 a member of the holoenzyme xanthine dehydrogenase (XDH)/XO family that generates ROS. XDH/XO expression and XO activity are increased in invasive cytotrophoblasts of pre-eclamptic women. 83 These changes, together with the above-mentioned increased production of ONOO -, result in release of ROS from the placenta into the maternal circulation. These ROS eventually contribute to widespread maternal endothelial dysfunction. The maternal level
The placental abnormalities described above have several maternal consequences (Figure 2 ). Although peripheral vascular resistance and blood pressure are substantially decreased in normal pregnancy, 101 increased peripheral vascular resistance is universally present in pre-eclampsia as a result of generalized vasoconstriction. Angiotensin II (Ang II) infusion can elicit an increased pressor response compared with normal pregnancy, 102 although this is not a universal finding. 103 Plasma renin activity and Ang II levels are low, 104 and platelet AT1 density is comparable to normal pregnancy, discounting the possibility that increased pressor response to Ang II in pre-eclampsia depends on increased receptor expression. Most vasoactive substances have been investigated with respect to their involvement in the maternal syndrome of pre-eclampsia. The relevance of endothelin-1, a potent vaso constrictor, remains unclear, as most studies (with some exceptions 81 ) have detected increased levels in the plasma of pre-eclamptic women. The vasoconstrictor thromboxane A 2 (TxA 2 ), normally generated by activated platelets, macrophages and the kidney, is synthesized in excessive amounts in severe pre-eclampsia. 105 Increased urinary excretion of TxA 2 meta bolites has been reported in some studies of pre-eclampsia but www.nature.com/clinicalpractice/neph not in others. 81 According to most reports, synthesis of vasodilatory mediators, such as prostacyclin (PGI 2 ) and NO, is reduced in preeclampsia. 81, 106, 107 Other authors have documented normal or even increased synthesis of NO. 70 In most studies, NO synthesis was evaluated indirectly by measuring plasma and urinary levels of its metabolites (nitrites and nitrates), which are also present in food and water. 70 So, variability in time, method of fluid sampling and dietary intake could explain discrepancies in the results of different studies. On the other hand, NO activity, measured as flow-mediated NO-dependent vasodilatation in resistancesized, subcutaneous vessels, is severely reduced in pre-eclampsia compared with normal pregnancy. 70 Increased plasma concentrations of the endo genous NO inhibitor asymmetric dimethyl arginine have also been found in preeclampsia, 108 although this was not confirmed. 109 Perhaps all of the changes in levels of vasoactive substances in pre-eclampsia reflect a generalized inflammatory response that activates the endothelium and circulating leukocytes.
Two new findings have shed light on the pathophysiology of the maternal syndrome of pre-eclampsia. First, a correlation between reduced uteroplacental blood flow in early or mid-pregnancy and the subsequent onset of pre-eclampsia. 110 Second, plasma and urinary levels of sFlt1 are higher than normal in patients with established pre-eclampsia, and begin to rise as early as 5 weeks before clinical onset. 65, 111 In a pilot cohort study, plasma levels of sFlt1 in women at 20 weeks of gestation with abnormal uterine perfusion were significant predictors of either pre-eclampsia or intrauterine growth retardation. 112 Concurrent measurement of uterine perfusion and sFlt1 levels could therefore be an early screening test for severe complications of pregnancy, although lacking specificity for pre-eclampsia. Repeated evaluation during the first two pregnancies of 93 women showed that sFlt1 serum levels were higher in the first than in the second pregnancy, indicating that enhanced sFlt1 secretion might account for the increased risk of pre-eclampsia among nulli parous women. 113 The way in which placental dysfunction relates to placental sFlt1 production remains unknown. Because hypoxia upregulates production of Flt1 in placental trophoblasts, 114, 115 restricted placental blood flow might increase placental production of sFlt1 to pathological levels, thus initiating the maternal syndrome. In normal primiparous women, plasma sFlt1 tends to increase during the last month of pregnancy, 65 despite normal uteroplacental blood flow. Therefore, what could differentiate preeclampsia from normal pregnancy is abnormal, early placental production and eventual high circulating concentrations of sFlt1, possibly secondary to placental vasculature constriction and hypoperfusion. Consistent with the scavenger effects of sFlt1, concentrations of unbound plasma VEGF and PlGF, and urinary PlGF, are decreased in pre-eclampsia. 65, 66, 116, 117 Evidence is emerging that lower than normal urinary PlGF levels mid-gestation might help predict development of pre-eclampsia. 117 So, circulating sFlt1 deprives the vasculature of the kidney, liver, brain and other organs of essential survival and maintenance signals, ultimately triggering the maternal vascular dysfunction of pre-eclampsia (Figure 3 ). There is evidence that, in addition to angiogenesis, VEGF induces vasodilation by enhancing endothelial synthesis of NO 68 and PGI 2 . As a consequence, www.nature.com/clinicalpractice/neph low circulating VEGF levels will increase vascular tone and cause hypertension, a hallmark of the maternal syndrome. The organs most affected by pre-eclampsia have fenestrated vascular endothelium, which is needed for physiological diffusion of water and solutes. Animal models have shown that VEGF is important in maintaining the health of fenestrated endothelium. 118 This implies that organs with fenestrated endo thelium could be prone to damage by sFlt1-mediated VEGF blockade. Pregnant and non-pregnant rats receiving sFlt1 via adenoviral transfection developed hyper tension, proteinuria and endo thelial abnormalities 66 reminiscent of those in pre-eclamptic women. Observed glomerular enlargement with occlusion of capillary loops by swelling and hypertrophy of endocapillary cells 66 mimics lesions of human pre-eclampsia. In the rat model, administration of VEGF reverses hypertension and proteinuria and ameliorates glomerular changes. 144 Administration of sFlt1 or VEGFneutralizing antibodies to normal mice caused severe proteinuria via glomerular endothelial cell detachment and damage, and down regulation of nephrin (a key protein of the glomerular filtration appara tus). 119 Similarly, neutralizing antibodies and VEGF-receptor inhibitors administered to cancer patients as antiangiogenic therapy can cause hypertension, proteinuria and coagulopathy. 120 Moreover, podocytespecific heterozygous deletion of the VegfA gene in mice caused a renal disease character ized by endotheliosis and proteinuria, the renal lesions of pre-eclampsia. 121 Together, these observations indicate that increased production of sFlt1 in pre-eclampsia contributes to the maternal symptoms. The gene encoding Flt1 in humans is on chromosome 13. Patients with trisomy 13 are at increased risk of developing pre-eclampsia compared with those with other trisomies and normal pregnant women. 122, 123 The contribution of the renin-angiotensin system to the maternal syndrome of preeclampsia is intriguing. As mentioned earlier, responsiveness to Ang II is enhanced in preeclampsia, but not as a result of increased AT1 levels. In omental vessels and platelets from preeclamptic women, there is a significant increase in heterodimerization between the AT1 and the B2 receptor of the vasodepressor bradykinin. 124 This does not occur in normal pregnancy. A fourfold to fivefold increase in B2 receptor protein levels was also documented, correlated with the increase in receptor heterodimerization. Expression of AT1-B2 heterodimer increased responsiveness to Ang II and conferred resistance on AT1 to inactivation by oxidative stress of preeclampsia. The mechanism by which the AT1-B2 heterodimer forms is speculative. It has been proposed that inflammation and ischemiafeatures of pre-eclampsia-increase expression of B2 receptors, which promotes hetero dimerization with the normally expressed AT1. This observation provides a plausible but not conclusive explanation for the enhanced vascular Ang-II-responsiveness of pre-eclampsia. The plasma of pre-eclamptic women also contains agonistic antibodies that target vascular smooth muscle AT1 77, 125 and dis appear after pregnancy; however, the origin of these antibodies and whether their dis appearance is consistent with the time course of the resolution of preeclampsia is unknown. An intriguing possibility is that the AT1-B2 receptor heterodimer acts as a neoantigen, eventually activating an immune response to generate the above-mentioned agonistic autoantibodies.
In addition to enhancing vascular tone, activation of AT1 (by Ang II or agonistic antibodies) and AT1-B2 receptor heterodimers generates ROS through long-term stimulation of endothelial and vascular smooth muscle nadh/NADPH OXIDASE. 77 AT1-agonistic antibodies can also target vascular smooth muscle angiotensin receptors to activate tissue factor, 125 and mesangial cells to release interleukin-6 and plasminogenactivator-inhibitor-1. 126 These findings might account for activation of coagulation and initiation of renal inflammation, other prominent features of the maternal disease. Furthermore, AT1-agonistic antibodies caused stimulation of plasminogen-activator-inhibitor-1 in human trophoblasts in vitro and perturbed trophoblast invasiveness, indicating that the antibodies might also have a role in impaired trophoblast invasion. 127 The importance of AT1-B2 heterodimerization and agonistic AT1 antibodies for the pathogenesis of the maternal syndrome depends to some extent on whether these factors are specific for pre-eclampsia or operate in other hypertensive and vascular disorders.
It has been postulated that oxidative stress resulting from placental ischemia is the fundamental abnormality leading to endo thelial damage in pre-eclampsia. Formation of oxidized LDLs is thought to initiate endothelial damage in atherosclerosis. In pre-eclampsia, fibrinoid GLOSSARY NADH/NADPH OXIDASE Multicomponent enzyme that catalyzes the oneelectron reduction of molecular oxygen to superoxide necrosis of vessel walls, with accumula tion of lipid-laden foam cells, is the hallmark of oxidized LDL. 128 Moreover, increased concentrations of IgG antibodies directed against oxidized LDL have been documented in pre-eclampsia, although not by all investigators. The possibility that oxidative stress has a role in determining endothelial dysfunction of pre-eclamptic maternal syndrome has sound biochemical underpinnings. ROS alter endothelial meta bolism by blocking mitochondrial electron transport, oxidizing proteins and initiating lipid peroxidation. 82 Lipid peroxides and ONOO -activate cyclooxygenase-1 and cyclo oxygenase-2, 129 thus increasing TxA 2 synthesis. As mentioned earlier, levels of this vaso constrictive prostanoid are elevated in pre-eclampsia. At the same time, lipid peroxides and ONOO -inhibit endothelial PGI 2 synthase, 129 thereby ultimately contributing to the TxA 2 -PGI 2 imbalance that precedes the onset of clinical symptoms of pre-eclampsia.
Unifying hypothesis
Although our understanding of the pathophysiology of pre-eclampsia is still incomplete, the recently published studies reviewed above provide elements for a unifying hypothesis (Figure 4) . We propose that pre-eclampsia might be a disease of placentation triggered by reduced activity or half-life of NO, secondary to a low tissue l-Arg concentration that is a consequence of excessive arginase expression. In response to the hypoxia that results from abnormal placentation and placental hypoperfusion, the placenta releases several factors into the maternal circulation, including sFlt1 and ROS, which initiate endothelial dysfunction and subsequent multisystem organ defects.
THERAPEUTIC PERSPECTIVES
Novel findings on the pathophysiology of the placental and maternal abnormalities of preeclampsia provide a rationale for potential prophylactic or therapeutic intervention. l-Arg or antioxidant supplementation, 130 Figure 4 Unifying hypothesis of pre-eclampsia pathophysiology. We propose that pre-eclampsia is a disease of placentation triggered by reduced activity or half-life of nitric oxide secondary to low placental L-arginine concentration, which is in turn related to excessive arginase II expression. Low L-arginine levels stimulate endothelial nitric oxide synthase to generate reactive oxygen species (e.g. peroxynitrite and hydroxyl radical) and locally exacerbate oxidative stress. Reduced flow through the placental L-argininenitric oxide pathway is also consistent with the higher resistance and hypoperfusion of the fetal-placental circulation. In response to the restricted placental blood flow and consequent hypoxia, the placenta releases into the maternal circulation a number of factors including soluble Fms-like tyrosine kinase 1 and reactive oxygen species, which initiate the vascular dysfunction characteristic of the maternal syndrome. Soluble Fms-like tyrosine kinase 1 is present at high concentrations in the blood of pre-eclamptic women, and administration of soluble Fms-like tyrosine kinase 1 to animals produces a maternal syndrome resembling that of pre-eclampsia. In a further attempt to ameliorate perfusion of the placenta as well as of the maternal organs involved in pre-eclampsia, upregulation of the B2 receptor for the vasodilator bradykinin occurs. The B2 receptors heterodimerize with the angiotensin II type 1 receptor, thereby increasing vascular and inflammatory responsiveness to angiotensin II, paradoxically reducing systemic organ perfusion and promoting generation of reactive oxygen species. Concomitant production of agonist angiotensin II type 1 receptor autoantibodies also contributes to oxidative stress. A positive-feedback loop is initiated that eventually results in the full-blown clinical syndrome of pre-eclampsia. Abs, antibodies; Ang II, angiotensin II; AT1, angiotensin II type 1 receptor; eNOS, endothelial nitric oxide synthase; L-Arg, L-arginine; MMP2, matrix metalloproteinase 2; MMP9, matrix metalloproteinase 9; NO, nitric oxide; O 2 -, superoxide anion; OH • , hydroxyl radical; PGI 2 , prostacyclin; sFlt1, soluble Fms-like tyrosine kinase 1; TxA 2 , thromboxane A 2 ; VEGF, vascular endothelial growth factor. degradation of this amino acid in the placenta by arginase II, and stimulate eNOS to release more NO and less superoxide anion. Preliminary data from a recent trial in 17 pre-eclamptic women showed that intravenous infusion of l-Arg was associated with a significant reduction of blood pressure. 131 In a larger placebo-controlled study, 3 weeks of l-Arg supplementation in preeclamptic women increased NO synthesis and lowered blood pressure compared with those given placebo. 132 In a preliminary study in women at high risk of placentation disorders (assessed as BILATERAL NOTCHING and high uterine artery resistance) chronic oral l-Arg supplementation from 10 weeks of gesta tion decreased mean arterial pressure and uterine artery resistance, improved endothelium-mediated vasodilatation and ameliorated perinatal outcome. 92 A combination of the antioxidant vitamins C and E given to pregnant women at high risk of pre-eclampsia reduced circulating levels of plasminogen-activator-inhibitor-1 (a marker of endothelial activation), lowered indices of oxidative stress and decreased the frequency of pre-eclampsia compared with placebo. 130, 133 These results indicate that oxidative stress might be a target for prevention of pre-eclampsia. Larger trials have begun in the US, Canada, Mexico, England and several develop ing nations. 134 The NIH has funded two antioxidant trials; the first is under way in Brazil and the second is being carried out in nulliparous women in the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. 135 These trials are expected to elucidate the effectiveness of antioxidants in prevention of pre-eclampsia.
Strategies to normalize circulating levels of free VEGF and PlGF by reducing the plasma concentration of sFlt1 or blocking its effects might be expected to ameliorate the systemic vascular and inflammatory response of the maternal syndrome. In mutant mice, Flt1 is not required for establishment of the maternal-fetal interface in the placenta, indicating that suppression or binding of sFlt1 to cure the maternal syndrome might not have adverse effects on the placenta. Clinical trials with VEGF are also being planned. 144 
CONCLUSIONS
The lack of a specific animal model of preeclampsia hinders experimental evaluation of pathogenetic mechanisms and effectiveness of potential new therapeutic approaches to this disorder. The model obtained by administering an l-Arg inhibitor to pregnant rats is the most commonly used. It might be a suitable background in which to test the effect of arginine deprivation on placental development, and to evaluate strategies to overcome such a defect with compounds that either prevent ONOOformation (such as arginase inhibitors and antioxidants) or block sFlt1 release from the placenta. The pre-eclampsia-like rat model induced by adenoviral-mediated administration of sFlt1 66 could also be used to test potential therapeutics.
Ongoing clinical studies are assessing the potential beneficial effect of l-Arg in women with pre-eclampsia; in particular, whether increasing l-Arg bioavailability might restore physiological NO production and inhibit ONOO -formation in pre-eclamptic placenta. This takes the form of a case-control pilot study of women given oral l-Arg supplementation from the time of diagnosis of pre-eclampsia to delivery, compared with placebo-treated preeclamptic women. Results could form the basis of a large, multicenter trial aimed at exploring whether prophylactic l-Arg supplementation reduces the incidence of pre-eclampsia in women at high risk of this disease, which is one of the leading causes of maternal and fetal morbidity and mortality. Hypothesis: hypoxia secondary to placental hypoperfusion induces release of soluble Fms-like tyrosine kinase 1 and reactive oxygen species into the maternal circulation, initiating endothelial dysfunction
■
The hypertension and proteinuria characteristic of pre-eclampsia might be ameliorated by supplementation with L-arginine or antioxidants, or by blocking Fms-like tyrosine kinase 1
